BRPI0911031A2 - compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes - Google Patents

compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes

Info

Publication number
BRPI0911031A2
BRPI0911031A2 BRPI0911031A BRPI0911031A BRPI0911031A2 BR PI0911031 A2 BRPI0911031 A2 BR PI0911031A2 BR PI0911031 A BRPI0911031 A BR PI0911031A BR PI0911031 A BRPI0911031 A BR PI0911031A BR PI0911031 A2 BRPI0911031 A2 BR PI0911031A2
Authority
BR
Brazil
Prior art keywords
piperidine compounds
substituted quinoxaline
bound
bound piperidine
quinoxaline
Prior art date
Application number
BRPI0911031A
Other languages
English (en)
Inventor
Jiangchao Yao
John W F Whitehead
Kouki Fuchino
Naoki Tsuno
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41077776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911031(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Publication of BRPI0911031A2 publication Critical patent/BRPI0911031A2/pt
Publication of BRPI0911031B1 publication Critical patent/BRPI0911031B1/pt
Publication of BRPI0911031B8 publication Critical patent/BRPI0911031B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

abstract not avaible
BRPI0911031A 2008-07-21 2009-07-20 compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes BRPI0911031B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8248208P 2008-07-21 2008-07-21
US61/082,482 2008-07-21
PCT/IB2009/006356 WO2010010458A1 (en) 2008-07-21 2009-07-20 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof

Publications (3)

Publication Number Publication Date
BRPI0911031A2 true BRPI0911031A2 (pt) 2017-01-17
BRPI0911031B1 BRPI0911031B1 (pt) 2021-05-11
BRPI0911031B8 BRPI0911031B8 (pt) 2021-05-25

Family

ID=41077776

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911031A BRPI0911031B8 (pt) 2008-07-21 2009-07-20 compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes

Country Status (31)

Country Link
US (6) US8476271B2 (pt)
EP (2) EP2324013B3 (pt)
JP (1) JP5416210B2 (pt)
KR (1) KR101333660B1 (pt)
CN (1) CN102105465B (pt)
AR (1) AR072578A1 (pt)
AU (1) AU2009275218C1 (pt)
BR (1) BRPI0911031B8 (pt)
CA (1) CA2730288C (pt)
CL (1) CL2011000148A1 (pt)
CO (1) CO6341627A2 (pt)
CY (1) CY1113485T1 (pt)
DK (1) DK2324013T6 (pt)
ES (1) ES2393849T7 (pt)
HR (1) HRP20120841T4 (pt)
IL (2) IL210549A (pt)
MX (1) MX2011000872A (pt)
MY (1) MY153948A (pt)
NZ (1) NZ590416A (pt)
PE (2) PE20140102A1 (pt)
PL (1) PL2324013T6 (pt)
PT (1) PT2324013E (pt)
RS (1) RS52590B2 (pt)
RU (1) RU2500678C2 (pt)
SG (1) SG192539A1 (pt)
SI (1) SI2324013T1 (pt)
SM (1) SMT201200053B (pt)
TW (2) TW201016697A (pt)
UA (1) UA99540C2 (pt)
WO (1) WO2010010458A1 (pt)
ZA (1) ZA201100189B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
MY150602A (en) 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
KR101333660B1 (ko) 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도
US9598447B2 (en) 2010-12-22 2017-03-21 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
AU2012293417A1 (en) 2011-08-10 2013-05-02 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
AU2012324015A1 (en) * 2011-12-01 2013-06-20 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thererof
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US10118927B2 (en) 2012-12-27 2018-11-06 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
JP7108041B2 (ja) * 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
CN113301957A (zh) * 2019-01-31 2021-08-24 普渡制药公司 取代的喹喔啉型桥接哌啶化合物的多晶型形式
MX2023013514A (es) 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
KR20250026332A (ko) * 2022-06-24 2025-02-25 퍼듀 퍼머 엘피 과민성 방광 증후군의 치료 또는 예방 방법
WO2025085818A1 (en) * 2023-10-19 2025-04-24 Purdue Pharma L.P. Sunobinop for use in method of treating alcohol use disorder

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5225402A (en) 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20020061554A1 (en) 1992-08-13 2002-05-23 Evans Christopher J. Orphan opioid receptor and recombinant materials for its production
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
EP0714299B1 (en) 1993-07-16 2002-04-24 Merck & Co. Inc. Benzoxazinone and benzopyrimidinone piperidinyl tocolytic oxytocin receptor antagonists
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ES2247604T3 (es) 1995-06-12 2006-03-01 G.D. SEARLE &amp; CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
JP3776201B2 (ja) 1997-04-17 2006-05-17 株式会社リコー 光記録媒体
ES2226129T3 (es) 1997-05-30 2005-03-16 Banyu Pharmaceutical Co., Ltd. Derivados de 2-0x0imidazol.
US6348461B1 (en) 1997-09-01 2002-02-19 Kyorin Pharmaceutical Co., Ltd. 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, addition salts thereof, and processes for the preparation of both
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
EP1067123B1 (en) 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
KR20010042298A (ko) 1998-03-31 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
US6686370B2 (en) 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
AU1816901A (en) 1999-12-06 2001-06-12 Euro-Celtique S.A. Benzimidazole compounds having nociceptin receptor affinity
AU6594401A (en) 2000-05-24 2001-12-03 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-quinoxalines
IL158484A0 (en) 2001-04-18 2004-05-12 Euro Celtique Sa Nociceptin analogs
KR100628292B1 (ko) 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
EP1385518B1 (en) 2001-04-18 2008-08-06 Euro-Celtique S.A. Benzimidazolone compounds
JP4489354B2 (ja) 2001-04-18 2010-06-23 ユーロ−セルティーク エス．エイ． スピロインデンおよびスピロインダン化合物類
RU2268883C2 (ru) 2001-04-18 2006-01-27 Эро-Селтик, С.А. Аналоги ноницептина и фармацевтическая композиция на их основе
EP1382598A4 (en) 2001-04-26 2005-03-23 Takeda Pharmaceutical NEW HETEROCYCLIC DERIVATIVES
DE10123163A1 (de) 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
EP1396488A1 (en) 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
MY126268A (en) * 2001-11-07 2006-09-29 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
WO2003062234A1 (en) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Quinoxaline compounds
US7026312B2 (en) 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
JP4056977B2 (ja) 2002-03-29 2008-03-05 田辺三菱製薬株式会社 睡眠障害治療薬
AU2003279276A1 (en) 2002-10-17 2004-05-04 Euro-Celtique S.A. Preparation of triazospiro compounds
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
AR045939A1 (es) 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
US20050228023A1 (en) 2003-12-19 2005-10-13 Sri International Agonist and antagonist ligands of the nociceptin receptor
DE10360793A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005075459A1 (en) 2004-02-03 2005-08-18 Euro-Celtique S.A. Synthesis of cyanoimino-benzoimidazoles
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
EP1676843A1 (en) 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
CA2612299A1 (en) 2005-06-17 2006-12-21 Pfizer Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
US7300947B2 (en) 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
PE20071159A1 (es) 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
EP1873150A1 (en) 2006-06-30 2008-01-02 Nikem Research S.R.L. Fluorinated indoleamides useful as ligands of the ORL-1 receptor
EP2397477B1 (en) * 2007-01-16 2014-03-05 Purdue Pharma LP Heterocyclic-substituted piperidine compounds and the uses thereof
BRPI0808025A2 (pt) 2007-03-01 2014-06-24 Mitsubishi Tanabe Pharma Corp Composto de benzimidazol e uso farmacêutico do mesmo
MY150602A (en) 2007-08-31 2014-01-30 Purdue Pharma Lp Subtituted-quinoxaline-type piperidine compounds and the uses thereof
CA2730606A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
KR101333660B1 (ko) 2008-07-21 2013-11-27 시오노기세이야쿠가부시키가이샤 치환-퀴녹살린-형 가교-피페리딘 화합물 및 그의 용도

Also Published As

Publication number Publication date
JP5416210B2 (ja) 2014-02-12
AU2009275218A1 (en) 2010-01-28
CA2730288C (en) 2016-09-13
MX2011000872A (es) 2011-07-29
HK1157763A1 (en) 2012-07-06
PL2324013T6 (pl) 2015-11-30
ZA201100189B (en) 2011-09-28
US20200223847A1 (en) 2020-07-16
HRP20120841T4 (hr) 2015-07-03
MY153948A (en) 2015-04-15
HRP20120841T1 (hr) 2012-11-30
US11111246B2 (en) 2021-09-07
CO6341627A2 (es) 2011-11-21
CN102105465A (zh) 2011-06-22
KR20110031993A (ko) 2011-03-29
US20160009717A1 (en) 2016-01-14
ES2393849T3 (es) 2012-12-28
PE20110416A1 (es) 2011-06-22
SG192539A1 (en) 2013-08-30
EP2324013A1 (en) 2011-05-25
EP2324013B1 (en) 2012-09-19
WO2010010458A1 (en) 2010-01-28
DK2324013T6 (en) 2014-12-15
AU2009275218C1 (en) 2015-02-05
IL210549A (en) 2017-09-28
IL210549A0 (en) 2011-03-31
US9890164B2 (en) 2018-02-13
JP2011528707A (ja) 2011-11-24
DK2324013T3 (da) 2012-11-19
US9145408B2 (en) 2015-09-29
RU2500678C2 (ru) 2013-12-10
IL254218A0 (en) 2017-10-31
SMT201200053B (it) 2013-01-14
PT2324013E (pt) 2012-12-24
SI2324013T1 (sl) 2012-12-31
PL2324013T3 (pl) 2013-05-31
US20180370971A1 (en) 2018-12-27
BRPI0911031B1 (pt) 2021-05-11
TW201016697A (en) 2010-05-01
PE20140102A1 (es) 2014-02-06
US10519156B2 (en) 2019-12-31
TW201329077A (zh) 2013-07-16
US20110178090A1 (en) 2011-07-21
US20130274265A1 (en) 2013-10-17
ES2393849T7 (es) 2015-01-28
EP2537844A1 (en) 2012-12-26
CN102105465B (zh) 2015-03-11
EP2324013B3 (en) 2014-10-22
AR072578A1 (es) 2010-09-08
NZ590416A (en) 2012-10-26
KR101333660B1 (ko) 2013-11-27
RU2011106375A (ru) 2012-08-27
CA2730288A1 (en) 2010-01-28
CY1113485T1 (el) 2016-06-22
US8476271B2 (en) 2013-07-02
AU2009275218B2 (en) 2012-11-08
UA99540C2 (ru) 2012-08-27
US20180148449A1 (en) 2018-05-31
BRPI0911031B8 (pt) 2021-05-25
RS52590B (sr) 2013-04-30
CL2011000148A1 (es) 2011-09-02
RS52590B2 (sr) 2018-05-31
TWI432434B (zh) 2014-04-01

Similar Documents

Publication Publication Date Title
BRPI0911031A2 (pt) compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes
BRPI0815327A2 (pt) &#34;compostos de piperidina do tipo quinoxalina substituída e os usos destes&#34;
BR112012003709A2 (pt) compostos heterocíclicos e usos dos mesmos
PT2448582T (pt) Compostos e composições terapêuticas
BRPI1005289A2 (pt) cabeça de cimentar
BRPI0908906A2 (pt) compostos heterocíclicos e usos dos mesmos
BRPI1010795A2 (pt) compostos antivirais
PT3812360T (pt) Compostos de monoclorotrifluoropropeno e composições e métodos utilizando os mesmos
DK2344478T3 (da) Cc-1065 analoger og deres konjugater
DK2215092T3 (da) Substitueret piperidino-dihydrothienopyrimidin
BRPI1011216A2 (pt) simulador de centro de dados
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
BRPI1014225A2 (pt) cosmético tipo folha
DK3300729T3 (da) Terapeutiske sammensætninger indeholdende macitentan
DE602007012430D1 (de) Stromschaltungsanordnung
BRPI0820410A2 (pt) Lactans substituídos terapêuticos
BRPI1012055A2 (pt) &#34;piperidinas substituídas&#34;
EP2242714A4 (en) Protective insert
BRPI0822782A2 (pt) composição farmacêutica que compreende rosuvastatina
DK2173197T3 (da) Fremgangsmåde
EP2348827A4 (en) IMMUNE UPPRIMED HOOKS
DE502008003022D1 (de) Häcksler
EP2493449A4 (en) TRANSPARENT COSMETICS COMPOSITION
HRP20160578T1 (hr) Supstituirani furankarboksamidi i njihova upotreba
BRPI1008993A2 (pt) marcadores fecais

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority

Free format text: PERDA DA PRIORIDADE US 61/082,482 DE 21/07/2008 REIVINDICADA NO PCT/IB2009/006356 POR NAO CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI 2390 DE 25/10/2016 DE MANEIRA SATISFATORIA. NAO FOI ENVIADO DOCUMENTO COMPROBATORIO DA TITULARIDADE DA PRIORIDADE REIVINDICADA PARA QUE SE CONFIRMASSE A CESSAO DA MESMA POR TODOS OS SEUS INVENTORES PARA AS EMPRESAS DEPOSITANTES DO PEDIDO PCT NO BRASIL. NO DOCUMENTO DA PRIORIDADE DISPONIVEL NA BIBLIOTECA VIRTUAL DA OMPI, O APLICANTE/INVENTOR DA PRIORIDADE US 61/082,482 ESTA COMO TBD (TO BE DETERMINATED), OU SEJA, NAO HOUVE A IDENTIFICACAO DO(S) MESMO(S) NO MOMENTO DO DEPOSITO DA PRIORIDADE, POR ISSO FOI FEITA A SOLICITACAO DE COMPROVACAO DA TITULARIDADE DA MESMA

B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: PURDUE PHARMA L.P. (US)